4F WavelinQ系统经皮创建动静脉瘘的6个月结果
本文汇总三项研究共120例患者,评估4F WavelinQ系统经皮创建自体动静脉瘘的安全性和有效性。手术成功率为96.7%,6个月一期、辅助一期和二期通畅率分别为71.9%±4.5%、80.7%±4.1%和87.8%±3.3%,设备相关严重不良事件发生率为2.5%。
要点
- 4F WavelinQ系统经皮创建动静脉瘘手术成功率达96.7%。
- 6个月一期通畅率为71.9%±4.5%,二期通畅率为87.8%±3.3%。
- 设备相关严重不良事件率为2.5%,无血管入路并发症报告。
核心结论
- 4F WavelinQ系统经皮创建自体透析瘘安全有效,6个月随访期内耐久性良好,严重并发症和再干预率低。
研究设计与样本
- 汇总三项研究(EASE研究32例、EASE-2研究24例、欧盟上市后临床随访研究64例)共120例患者,随访6个月。
主要发现
- 手术成功率为116/120(96.7%)。
- 6个月一期、辅助一期和二期通畅率分别为71.9%±4.5%、80.7%±4.1%和87.8%±3.3%。
- 成熟时间平均41±17天,成功穿刺时间平均68±51天。
- 设备相关严重不良事件3/120(2.5%),手术相关严重不良事件7/120(5.8%)。
- 通路再干预23例(19.2%),其中因EndoAVF成熟再干预13/120(10.8%),因维持再干预11/120(9.2%)。
临床怎么用
- 4F设备可在桡动脉与桡静脉或尺动脉与尺静脉之间经皮创建动静脉瘘。
- 该设备可作为开放手术或较大口径腔内设备创建动静脉瘘的经皮替代选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Percutaneous devices for creation of native arteriovenous fistulae offer an alternative to traditional open surgical techniques. The 4F WavelinQ EndoAVF System was developed as a lower profile alternative to facilitate access through smaller vessels and minimize access site complications; The current report is the original first experience of this device, assessing outcome in 120 patients followed for 6 months. METHODS: The use of the 4F WavelinQ system in three studies, EASE (32 patients), EASE-2 (24 patients), and the EU postmarket clinical follow-up study (64 patients) was aggregated and analyzed. Patients were followed with duplex ultrasound at discharge and follow-up visits at 1, 3, and 6 months. Primary, assisted primary, and secondary patency rates were evaluated as Kaplan-Meier estimates and standard errors. Time to maturity and time to successful cannulation were defined as the mean ± standard deviation days from the procedure in patients enrolled on dialysis. RESULTS: Procedural success was achieved in 116 patients (96.7%). Primary, assisted-primary, and secondary 6-month patency rates were 71.9% ± 4.5%, 80.7% ± 4.1%, and 87.8% ± 3.3%, respectively. Time to maturity averaged 41 ± 17 days. Time to successful cannulation averaged 68 ± 51 days. Device-related serious adverse events were reported in 3 of 120 patients (2.5%) and procedure-related serious adverse events occurred in 7 of 120 patients (5.8%). Arterial or venous access complications were not reported in any of the patients. Access circuit reinterventions were performed in 23 patients (19.2%), split between those performed for EndoAVF maturation (13/120 [10.8%]) and maintenance (11/120 [9.2%]). CONCLUSIONS: Percutaneous creation of native dialysis fistulae with the 4F WavelinQ EndoAVF System is safe and effective, with favorable durability and a low rate of serious complications and reinterventions through 6-month follow-up. Use of the 4F device allows for percutaneous fistula creation between the radial artery and radial vein or the ulnar artery and ulnar vein. These findings suggest that the 4F device is a useful percutaneous alternative to open surgical AVF or endovascular AVF with larger bore devices.
引用
- Berland T, Clement J, Inston N, et al. Percutaneous arteriovenous fistula creation with the 4F WavelinQ EndoAVF System. J Vasc Surg. 2021. PMID: 34601046. doi:10.1016/j.jvs.2021.09.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。